Accedi

Bibliografie tematiche / FK-506 (Drug)

Indice

Articoli di riviste
Tesi
Libri
Capitoli di libri

Letteratura scientifica selezionata sul tema "FK-506 (Drug)"

Autore: Grafiati

Pubblicato: 4 giugno 2021

Ultima modifica: 19 febbraio 2022

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "FK-506 (Drug)".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Articoli di riviste sul tema "FK-506 (Drug)"

1

Shaw, L. M., and K. L. Brayman. "FK-506 therapeutic drug monitoring." Clinical Chemistry 40, no. 12 (December 1, 1994): 2207–8. http://dx.doi.org/10.1093/clinchem/40.12.2207.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Winkler, M., B. Ringe, J. Baumann, M. Loss, K. Wonigeit, and R. Pichlmayr. "Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression." Clinical Chemistry 40, no. 12 (December 1, 1994): 2247–53. http://dx.doi.org/10.1093/clinchem/40.12.2247.

Testo completo

Abstract (sommario):

Abstract By retrospective analysis of 13,000 blood samples obtained from 248 patients receiving FK 506 therapy, we compared the suitability of plasma with that of whole blood as the matrix for therapeutic drug monitoring of FK 506. The plasma concentrations did not correlate with the concentrations in whole blood (r = 0.56). In contrast to plasma samples (analyzed by enzyme immunoassay), FK 506 was detectable in all whole-blood samples (analyzed by enzyme immunoassay/microparticle enzyme immunoassay). The inter- and intraindividual variations of FK 506 measurements were greater in plasma than

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Dumont, F. J., M. J. Staruch, S. L. Koprak, J. J. Siekierka, C. S. Lin, R. Harrison, T. Sewell, V. M. Kindt, T. R. Beattie, and M. Wyvratt. "The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin." Journal of Experimental Medicine 176, no. 3 (September 1, 1992): 751–60. http://dx.doi.org/10.1084/jem.176.3.751.

Testo completo

Abstract (sommario):

FK-506 inhibits Ca(2+)-dependent transcription of lymphokine genes in T cells, and thereby acts as a powerful immunosuppressant. However, its potential therapeutic applications may be seriously limited by several side effects, including nephrotoxicity and neurotoxicity. At present, it is unclear whether these immunosuppressive and toxic effects result from interference with related biochemical processes. FK-506 is known to interact with FK-binding protein-12 (FKBP-12), an abundant cytosolic protein with cis-trans peptidyl-prolyl isomerase activity (PPIase) activity. Because rapamycin (RAP) sim

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Rokaw, M. D., M. E. West, P. M. Palevsky, and J. P. Johnson. "FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells." American Journal of Physiology-Cell Physiology 271, no. 1 (July 1, 1996): C194—C202. http://dx.doi.org/10.1152/ajpcell.1996.271.1.c194.

Testo completo

Abstract (sommario):

The immunosuppressants cyclosporin A (CyA), FK-506, and rapamycin (RAP) have multiple actions on target cells that appear to be mediated by interaction of drug-binding protein complexes. Both FK-506 and CyA, but not RAP, inhibit the Ca2(+)-dependent phosphatase, calcineurin, and in so doing have been found to inhibit Na(+)-K(+)-ATPase activity in various nephron segments. Of interest, FK-506 and RAP, but not CyA, are bound by the steroid receptor-associated FK-506-binding heat shock protein of 56 kDa, HSP56. To determine the physiological effect of this interaction on a steroid-mediated phenom

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Di Padova, F. E. "Pharmacology of CsA and FK-506." Perspectives in Drug Discovery and Design 2, no. 1 (August 1994): 49–56. http://dx.doi.org/10.1007/bf02171736.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Goulet, Mark T., Kathleen M. Rupprecht, Peter J. Sinclair, Matthew J. Wyvratt, and William H. Parsons. "The medicinal chemistry of FK-506." Perspectives in Drug Discovery and Design 2, no. 1 (August 1994): 145–62. http://dx.doi.org/10.1007/bf02171741.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Petros, Andrew M., Gerd Gemmecker, Placido Neri, Edward T. Olejniczak, David Nettesheim, Robert X. Xu, Earl G. Gubbins, Harriet Smith, and Stephen W. Fesik. "NMR studies of an FK-506 analog, [U-carbon-13]ascomycin, bound to FK-506-binding protein." Journal of Medicinal Chemistry 35, no. 13 (June 1992): 2467–73. http://dx.doi.org/10.1021/jm00091a015.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Kay, John E., Senam E. A. Doe, and C. Robin Benzie. "The mechanism of action of the immunosuppressive drug FK-506." Cellular Immunology 124, no. 1 (November 1989): 175–81. http://dx.doi.org/10.1016/0008-8749(89)90121-4.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

O'connor, Stephen P., Robert L. Ellsworth, Mary Nallin Omstead, Rosalind G. Jenkins, and Louis Kaplan. "The preparation of 14C-labeled FK-506." Journal of Labelled Compounds and Radiopharmaceuticals 31, no. 2 (February 1992): 103–8. http://dx.doi.org/10.1002/jlcr.2580310205.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Jusko, William J. "Analysis of Tacrolimus (FK 506) in Relation to Therapeutic Drug Monitoring." Therapeutic Drug Monitoring 17, no. 6 (December 1995): 596–601. http://dx.doi.org/10.1097/00007691-199512000-00009.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Più fonti

Tesi sul tema "FK-506 (Drug)"

1

Karlsson, Håkan. "Influence of FK506 on certain aspects of lymphocyte activation and lymphocyte-endothelial cell interactions in vitro." Lund : Dept. of Medical Microbiology, Section of Clinical Immunology, Lund University, 1997. http://catalog.hathitrust.org/api/volumes/oclc/39799195.html.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Whitaker, Audie D. "The role of interferon-gamma in cyclosporine A or FK-506 treated L. major infected mice." Virtual Press, 1999. http://liblink.bsu.edu/uhtbin/catkey/1138295.

Testo completo

Abstract (sommario):

Certain strains of mice, e.g. C57BL/6, are highly resistant to serious infections with the protozoan pathogen, Leishmania major, whereas other strains, e.g. BALB/c, are not. It has beenproposed that interferon gamma (IFN-y) is one of the most critical lymphokines produced in a protective response to these intracellular pathogens. IFN-y has been classified as a Thi lymphokine produced by the Thl subset of T lymphocytes which not only activates macrophages to kill the protozoa but also helps regulates the immune system overall to form a lasting immunity to the microorganism (4,19). Mice suscepti

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Potter, Shannon M. "The role of cyclosporin A, leptin, and FK-506 in Leishmania major infections in mice." Muncie, Ind. : Ball State University, 2009. http://cardinalscholar.bsu.edu/467.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Jones, Terence Edward. "Economically beneficial drug interactions with cyclosporin and tacroliumus : clinical studies in recipients of kidney and liver transplants." Title page, contents and abstract only, 2000. http://web4.library.adelaide.edu.au/theses/09PH/09phj79.pdf.

Testo completo

Abstract (sommario):

Bibliography: leaves 234-257. Three separate clinical studies in organ transplant recipients are presented. The aims are to examine fundamental questions regarding the clinically and economically important pharmokinetic interaction between diltiazem and cyclosporin, an interaction widely utilised in organ transplantation. The data contained should assist the development of soundly based policies that will ensure a benefit exists before a sparing agent is coprescribed, and that the lowest effective dose of sparing agent is used.

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Soubhia, Rosa Maria Cordeiro. "Avaliação dos efeitos nefrotóxicos da associação do tacrolimus (FK 506) e antiinflamatórios não-hormonais em ratos." Faculdade de Medicina de São José do Rio Preto, 2005. http://bdtd.famerp.br/handle/tede/166.

Testo completo

Abstract (sommario):

Made available in DSpace on 2016-01-26T12:51:42Z (GMT). No. of bitstreams: 1 rosasoubhia_tese.pdf: 792706 bytes, checksum: bba71696e22270729d09c3130cc047eb (MD5) Previous issue date: 2005-05-25<br>Introduction: Tacrolimus (FK 506) is a potent immunosuppressive drug that may cause nephrotoxicity decreasing the renal blood flow (RBF) and glomerular filtration rate (GFR). Conventional non-steroidal anti-inflammatory drugs (NSAIDs) may cause nephrotoxicity, interfering with renal hemodynamics and fluid and eletrolyte homeostasis. Recently, new selective COX-2 inhibitors have been developed produ

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Toske, Steven Gerald. "Part I : synthesis of azetidin-2-ones from pyrazolidin-3-ones ; Part II : synthesis of a subunit of the immunosuppressant FK-506." Thesis, 1993. http://hdl.handle.net/1957/35676.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Sinswat, Prapasri 1972. "Enhancing the delivery of poorly water soluble drugs using particle engineering technologies." 2006. http://hdl.handle.net/2152/13124.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Overhoff, Kirk Alan. "Improved oral bioavailability of poorly water soluble drugs using rapid freezing processes." 2006. http://hdl.handle.net/2152/13125.

Testo completo

Abstract (sommario):

A growing number of therapeutic compounds currently being developed by pharmaceutical companies are poorly water soluble leading to limited and/or erratic bioavailability. The rate limiting step for absorption of these compounds is dependent on the dissolution and apparent solubility. Nanoparticle formation has been exploited as a method to improve the bioavailability of these poorly water soluble active pharmaceutical ingredients (API) by increasing the dissolution rates and apparent solubilities. The influence of hydrophilic stabilizers in powder compositions prepared by the spray freezing i

Gli stili APA, Harvard, Vancouver, ISO e altri

Libri sul tema "FK-506 (Drug)"

1

FK506 and organ transplantation. Austin: R.G. Landes, 1994.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Raptis, Dimitrios, and Manousos-Georgios Pramateftakis. Tacrolimus: Effectiveness, Safety and Drug Interactions. Nova Science Publishers, Incorporated, 2013.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Tacrolimus in organ transplantation: Prevention and treatment of allograft rejections. Lengerich: Pabst Science Publishers, 1998.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Toske, Steven Gerald. Part I: Synthesis of azetidin-2-ones from pyrazolidin-3-ones ; Part II : synthesis of a subunit of the immunosuppressant FK-506. 1993.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Thomas, Ruzicka, and Reitamo Sakari, eds. Tacrolimus ointment: A topical immunomodulator for atopic dermatitis. Berlin: Springer, 2004.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

(Editor), T. Ruzicka, and S. Reitamo (Editor), eds. Tacrolimus. Springer, 2003.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Tacrolimus ointment: A topical immunomodulator for atopic dermatitis. Berlin: Springer, 2003.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Capitoli di libri sul tema "FK-506 (Drug)"

1

Rossaro, L., S. R. Dowd, V. Simplaceanu, R. Naccarato, D. H. Van Thiel, and C. Ho. "Effect of FK 506 and Cyclosporins on Model Membranes Studied by Nuclear Magnetic Resonance Spectroscopy." In Drugs and the Liver: High Risk Patients and Transplantation, 177–84. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1994-8_29.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

"Tacrolimus (FK-506)." In Drug Therapy in Dermatology, 172–81. CRC Press, 2000. http://dx.doi.org/10.1201/b14006-12.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

KOCIENSKI, PHILIP, MICHAEL STOCKS, and DAVID K. DONALD. "Recent Progress in Research on the Immunosuppressant FK-506." In Chirality in Drug Design and Synthesis, 131–65. Elsevier, 1990. http://dx.doi.org/10.1016/b978-0-12-136670-4.50014-x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!